recombinant maltose Search Results


maltose binding protein recombinant protein  (Bio-Techne corporation)
94
Bio-Techne corporation maltose binding protein recombinant protein
Maltose Binding Protein Recombinant Protein, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+maltose/Maltose+Binding+Protein+Recombinant+Protein/bio-techne+corporation___nbc1-18538
Average 94 stars, based on 1 article reviews
maltose binding protein recombinant protein - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
recombinant maltose  (Novus Biologicals)
92
Novus Biologicals recombinant maltose
Ferritin heavy chain 1 (FTH1) competes with B19V VP1u for binding to hTfR, thereby inhibiting B19V internalization and replication in CD36 + EPCs. (A&B) BLI analysis of FTH1 inhibition of GST-VP1u RBD binding to hTfR ECD . (A) Experimental scheme. hTfR ECD was immobilized on Ni-NTA BLI biosensors, then introduced into the kinetic buffer with or without FTH1, and subsequently into buffer containing GST-VP1u RBD <t>.</t> <t>Maltose-binding</t> protein (MBP) served as a control for non-specific binding. (B) Dose-dependent inhibition of VP1u binding to hTfR by FTH1. Sensograms show progressively reduced association and dissociation of hTfR ECD with GST-VP1u RBD after the introduction of FTH1 at the indicated concentrations. MBP served as a control at 4 µM. (C) Quantification of FTH1 inhibition of B19V internalization. CD36 + EPCs were incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C, followed by B19V infection (MOI=3,000) at 37°C for 1 h. After treatment with trypsin, the cells were washed with PBS, and viral DNA was extracted for quantification of internalized B19V by relative viral DNA levels normalized to mitochondrial DNA. (D) FTH1 inhibits B19V infection. CD36 + EPCs were pre-incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C followed by B19V infection (MOI=1,000) at 37°C for 1 day. At 1 dpi, the cells were collected for quantification of B19V DNA levels. Data are presented relative to the corresponding control-treated cell group at each concentration. Experiments were performed in triplicate, and data shown are mean ± SD, and were analyzed by one-way ANOVA with Dunnett’s test (****P < 0.0001) (E&F) Cell cycle analysis. An EdU incorporation assay was performed in CD36 + EPCs with the indicated treatments, followed by flow cytometry analysis. (E) Flow cytometry histograms. Representative histograms show the cell cycles of mock, 10 µM FTH1-, and 10 µM MBP-treated CD36 + EPCs. (F) Quantification of the percentage of the indicated cell populations in G2/M, S, or G1 phase. Data shown are the mean ± SD from three independent experiments. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; ns, not significant).
Recombinant Maltose, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+maltose/Maltose+Binding+Protein+Recombinant+Protein/bio_rxiv__64898__2026__04__02__715920-222-0-8
Average 92 stars, based on 1 article reviews
recombinant maltose - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier
mbp  (Boster Bio)
94
Boster Bio mbp
Ferritin heavy chain 1 (FTH1) competes with B19V VP1u for binding to hTfR, thereby inhibiting B19V internalization and replication in CD36 + EPCs. (A&B) BLI analysis of FTH1 inhibition of GST-VP1u RBD binding to hTfR ECD . (A) Experimental scheme. hTfR ECD was immobilized on Ni-NTA BLI biosensors, then introduced into the kinetic buffer with or without FTH1, and subsequently into buffer containing GST-VP1u RBD <t>.</t> <t>Maltose-binding</t> protein (MBP) served as a control for non-specific binding. (B) Dose-dependent inhibition of VP1u binding to hTfR by FTH1. Sensograms show progressively reduced association and dissociation of hTfR ECD with GST-VP1u RBD after the introduction of FTH1 at the indicated concentrations. MBP served as a control at 4 µM. (C) Quantification of FTH1 inhibition of B19V internalization. CD36 + EPCs were incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C, followed by B19V infection (MOI=3,000) at 37°C for 1 h. After treatment with trypsin, the cells were washed with PBS, and viral DNA was extracted for quantification of internalized B19V by relative viral DNA levels normalized to mitochondrial DNA. (D) FTH1 inhibits B19V infection. CD36 + EPCs were pre-incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C followed by B19V infection (MOI=1,000) at 37°C for 1 day. At 1 dpi, the cells were collected for quantification of B19V DNA levels. Data are presented relative to the corresponding control-treated cell group at each concentration. Experiments were performed in triplicate, and data shown are mean ± SD, and were analyzed by one-way ANOVA with Dunnett’s test (****P < 0.0001) (E&F) Cell cycle analysis. An EdU incorporation assay was performed in CD36 + EPCs with the indicated treatments, followed by flow cytometry analysis. (E) Flow cytometry histograms. Representative histograms show the cell cycles of mock, 10 µM FTH1-, and 10 µM MBP-treated CD36 + EPCs. (F) Quantification of the percentage of the indicated cell populations in G2/M, S, or G1 phase. Data shown are the mean ± SD from three independent experiments. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; ns, not significant).
Mbp, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+maltose/e%2Ecoli+MBP+Recombinant+Protein/pm34555716-104-52-54
Average 94 stars, based on 1 article reviews
mbp - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
maltose binding protein (mbp)-cdc25 recombinant enzyme  (GTP Technology)
90
GTP Technology maltose binding protein (mbp)-cdc25 recombinant enzyme
Ferritin heavy chain 1 (FTH1) competes with B19V VP1u for binding to hTfR, thereby inhibiting B19V internalization and replication in CD36 + EPCs. (A&B) BLI analysis of FTH1 inhibition of GST-VP1u RBD binding to hTfR ECD . (A) Experimental scheme. hTfR ECD was immobilized on Ni-NTA BLI biosensors, then introduced into the kinetic buffer with or without FTH1, and subsequently into buffer containing GST-VP1u RBD <t>.</t> <t>Maltose-binding</t> protein (MBP) served as a control for non-specific binding. (B) Dose-dependent inhibition of VP1u binding to hTfR by FTH1. Sensograms show progressively reduced association and dissociation of hTfR ECD with GST-VP1u RBD after the introduction of FTH1 at the indicated concentrations. MBP served as a control at 4 µM. (C) Quantification of FTH1 inhibition of B19V internalization. CD36 + EPCs were incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C, followed by B19V infection (MOI=3,000) at 37°C for 1 h. After treatment with trypsin, the cells were washed with PBS, and viral DNA was extracted for quantification of internalized B19V by relative viral DNA levels normalized to mitochondrial DNA. (D) FTH1 inhibits B19V infection. CD36 + EPCs were pre-incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C followed by B19V infection (MOI=1,000) at 37°C for 1 day. At 1 dpi, the cells were collected for quantification of B19V DNA levels. Data are presented relative to the corresponding control-treated cell group at each concentration. Experiments were performed in triplicate, and data shown are mean ± SD, and were analyzed by one-way ANOVA with Dunnett’s test (****P < 0.0001) (E&F) Cell cycle analysis. An EdU incorporation assay was performed in CD36 + EPCs with the indicated treatments, followed by flow cytometry analysis. (E) Flow cytometry histograms. Representative histograms show the cell cycles of mock, 10 µM FTH1-, and 10 µM MBP-treated CD36 + EPCs. (F) Quantification of the percentage of the indicated cell populations in G2/M, S, or G1 phase. Data shown are the mean ± SD from three independent experiments. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; ns, not significant).
Maltose Binding Protein (Mbp) Cdc25 Recombinant Enzyme, supplied by GTP Technology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+maltose/maltose+binding+protein++mbp++cdc25+recombinant+enzyme/pm19065668-20-5-14
Average 90 stars, based on 1 article reviews
maltose binding protein (mbp)-cdc25 recombinant enzyme - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
maltose-binding protein (mbp)-tagged recombinant proteins of wild-type aak1d157a  (Schmid GmbH)
90
Schmid GmbH maltose-binding protein (mbp)-tagged recombinant proteins of wild-type aak1d157a
Ferritin heavy chain 1 (FTH1) competes with B19V VP1u for binding to hTfR, thereby inhibiting B19V internalization and replication in CD36 + EPCs. (A&B) BLI analysis of FTH1 inhibition of GST-VP1u RBD binding to hTfR ECD . (A) Experimental scheme. hTfR ECD was immobilized on Ni-NTA BLI biosensors, then introduced into the kinetic buffer with or without FTH1, and subsequently into buffer containing GST-VP1u RBD <t>.</t> <t>Maltose-binding</t> protein (MBP) served as a control for non-specific binding. (B) Dose-dependent inhibition of VP1u binding to hTfR by FTH1. Sensograms show progressively reduced association and dissociation of hTfR ECD with GST-VP1u RBD after the introduction of FTH1 at the indicated concentrations. MBP served as a control at 4 µM. (C) Quantification of FTH1 inhibition of B19V internalization. CD36 + EPCs were incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C, followed by B19V infection (MOI=3,000) at 37°C for 1 h. After treatment with trypsin, the cells were washed with PBS, and viral DNA was extracted for quantification of internalized B19V by relative viral DNA levels normalized to mitochondrial DNA. (D) FTH1 inhibits B19V infection. CD36 + EPCs were pre-incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C followed by B19V infection (MOI=1,000) at 37°C for 1 day. At 1 dpi, the cells were collected for quantification of B19V DNA levels. Data are presented relative to the corresponding control-treated cell group at each concentration. Experiments were performed in triplicate, and data shown are mean ± SD, and were analyzed by one-way ANOVA with Dunnett’s test (****P < 0.0001) (E&F) Cell cycle analysis. An EdU incorporation assay was performed in CD36 + EPCs with the indicated treatments, followed by flow cytometry analysis. (E) Flow cytometry histograms. Representative histograms show the cell cycles of mock, 10 µM FTH1-, and 10 µM MBP-treated CD36 + EPCs. (F) Quantification of the percentage of the indicated cell populations in G2/M, S, or G1 phase. Data shown are the mean ± SD from three independent experiments. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; ns, not significant).
Maltose Binding Protein (Mbp) Tagged Recombinant Proteins Of Wild Type Aak1d157a, supplied by Schmid GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+maltose/maltose+binding+protein++mbp++tagged+recombinant+proteins+of+wild+type+aak1d157a/pm37440281-58-11-40
Average 90 stars, based on 1 article reviews
maltose-binding protein (mbp)-tagged recombinant proteins of wild-type aak1d157a - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
competitor protein recombinant maltose binding protein mbp  (Obetech LLC)
90
Obetech LLC competitor protein recombinant maltose binding protein mbp
Ferritin heavy chain 1 (FTH1) competes with B19V VP1u for binding to hTfR, thereby inhibiting B19V internalization and replication in CD36 + EPCs. (A&B) BLI analysis of FTH1 inhibition of GST-VP1u RBD binding to hTfR ECD . (A) Experimental scheme. hTfR ECD was immobilized on Ni-NTA BLI biosensors, then introduced into the kinetic buffer with or without FTH1, and subsequently into buffer containing GST-VP1u RBD <t>.</t> <t>Maltose-binding</t> protein (MBP) served as a control for non-specific binding. (B) Dose-dependent inhibition of VP1u binding to hTfR by FTH1. Sensograms show progressively reduced association and dissociation of hTfR ECD with GST-VP1u RBD after the introduction of FTH1 at the indicated concentrations. MBP served as a control at 4 µM. (C) Quantification of FTH1 inhibition of B19V internalization. CD36 + EPCs were incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C, followed by B19V infection (MOI=3,000) at 37°C for 1 h. After treatment with trypsin, the cells were washed with PBS, and viral DNA was extracted for quantification of internalized B19V by relative viral DNA levels normalized to mitochondrial DNA. (D) FTH1 inhibits B19V infection. CD36 + EPCs were pre-incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C followed by B19V infection (MOI=1,000) at 37°C for 1 day. At 1 dpi, the cells were collected for quantification of B19V DNA levels. Data are presented relative to the corresponding control-treated cell group at each concentration. Experiments were performed in triplicate, and data shown are mean ± SD, and were analyzed by one-way ANOVA with Dunnett’s test (****P < 0.0001) (E&F) Cell cycle analysis. An EdU incorporation assay was performed in CD36 + EPCs with the indicated treatments, followed by flow cytometry analysis. (E) Flow cytometry histograms. Representative histograms show the cell cycles of mock, 10 µM FTH1-, and 10 µM MBP-treated CD36 + EPCs. (F) Quantification of the percentage of the indicated cell populations in G2/M, S, or G1 phase. Data shown are the mean ± SD from three independent experiments. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; ns, not significant).
Competitor Protein Recombinant Maltose Binding Protein Mbp, supplied by Obetech LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+maltose/competitor+protein+recombinant+maltose+binding+protein+mbp/pmc03407196-125-33-42
Average 90 stars, based on 1 article reviews
competitor protein recombinant maltose binding protein mbp - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
maltose binding protein mbp  (Aviva Systems)
90
Aviva Systems maltose binding protein mbp
Ferritin heavy chain 1 (FTH1) competes with B19V VP1u for binding to hTfR, thereby inhibiting B19V internalization and replication in CD36 + EPCs. (A&B) BLI analysis of FTH1 inhibition of GST-VP1u RBD binding to hTfR ECD . (A) Experimental scheme. hTfR ECD was immobilized on Ni-NTA BLI biosensors, then introduced into the kinetic buffer with or without FTH1, and subsequently into buffer containing GST-VP1u RBD <t>.</t> <t>Maltose-binding</t> protein (MBP) served as a control for non-specific binding. (B) Dose-dependent inhibition of VP1u binding to hTfR by FTH1. Sensograms show progressively reduced association and dissociation of hTfR ECD with GST-VP1u RBD after the introduction of FTH1 at the indicated concentrations. MBP served as a control at 4 µM. (C) Quantification of FTH1 inhibition of B19V internalization. CD36 + EPCs were incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C, followed by B19V infection (MOI=3,000) at 37°C for 1 h. After treatment with trypsin, the cells were washed with PBS, and viral DNA was extracted for quantification of internalized B19V by relative viral DNA levels normalized to mitochondrial DNA. (D) FTH1 inhibits B19V infection. CD36 + EPCs were pre-incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C followed by B19V infection (MOI=1,000) at 37°C for 1 day. At 1 dpi, the cells were collected for quantification of B19V DNA levels. Data are presented relative to the corresponding control-treated cell group at each concentration. Experiments were performed in triplicate, and data shown are mean ± SD, and were analyzed by one-way ANOVA with Dunnett’s test (****P < 0.0001) (E&F) Cell cycle analysis. An EdU incorporation assay was performed in CD36 + EPCs with the indicated treatments, followed by flow cytometry analysis. (E) Flow cytometry histograms. Representative histograms show the cell cycles of mock, 10 µM FTH1-, and 10 µM MBP-treated CD36 + EPCs. (F) Quantification of the percentage of the indicated cell populations in G2/M, S, or G1 phase. Data shown are the mean ± SD from three independent experiments. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; ns, not significant).
Maltose Binding Protein Mbp, supplied by Aviva Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+maltose/MBP+E%2EColi+-+Recombinant+E%2EColi+Maltose+Binding+Protein/pm20955243-210-4-11
Average 90 stars, based on 1 article reviews
maltose binding protein mbp - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
recombinant maltose-binding os4bglu18  (Promega)
90
Promega recombinant maltose-binding os4bglu18
Ferritin heavy chain 1 (FTH1) competes with B19V VP1u for binding to hTfR, thereby inhibiting B19V internalization and replication in CD36 + EPCs. (A&B) BLI analysis of FTH1 inhibition of GST-VP1u RBD binding to hTfR ECD . (A) Experimental scheme. hTfR ECD was immobilized on Ni-NTA BLI biosensors, then introduced into the kinetic buffer with or without FTH1, and subsequently into buffer containing GST-VP1u RBD <t>.</t> <t>Maltose-binding</t> protein (MBP) served as a control for non-specific binding. (B) Dose-dependent inhibition of VP1u binding to hTfR by FTH1. Sensograms show progressively reduced association and dissociation of hTfR ECD with GST-VP1u RBD after the introduction of FTH1 at the indicated concentrations. MBP served as a control at 4 µM. (C) Quantification of FTH1 inhibition of B19V internalization. CD36 + EPCs were incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C, followed by B19V infection (MOI=3,000) at 37°C for 1 h. After treatment with trypsin, the cells were washed with PBS, and viral DNA was extracted for quantification of internalized B19V by relative viral DNA levels normalized to mitochondrial DNA. (D) FTH1 inhibits B19V infection. CD36 + EPCs were pre-incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C followed by B19V infection (MOI=1,000) at 37°C for 1 day. At 1 dpi, the cells were collected for quantification of B19V DNA levels. Data are presented relative to the corresponding control-treated cell group at each concentration. Experiments were performed in triplicate, and data shown are mean ± SD, and were analyzed by one-way ANOVA with Dunnett’s test (****P < 0.0001) (E&F) Cell cycle analysis. An EdU incorporation assay was performed in CD36 + EPCs with the indicated treatments, followed by flow cytometry analysis. (E) Flow cytometry histograms. Representative histograms show the cell cycles of mock, 10 µM FTH1-, and 10 µM MBP-treated CD36 + EPCs. (F) Quantification of the percentage of the indicated cell populations in G2/M, S, or G1 phase. Data shown are the mean ± SD from three independent experiments. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; ns, not significant).
Recombinant Maltose Binding Os4bglu18, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+maltose/recombinant+maltose+binding+os4bglu18/10__1016_slash_j__envexpbot__2022__105076-96-2-14
Average 90 stars, based on 1 article reviews
recombinant maltose-binding os4bglu18 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
recombinant maltose binding protein (mbp  (Obetech LLC)
90
Obetech LLC recombinant maltose binding protein (mbp
Ferritin heavy chain 1 (FTH1) competes with B19V VP1u for binding to hTfR, thereby inhibiting B19V internalization and replication in CD36 + EPCs. (A&B) BLI analysis of FTH1 inhibition of GST-VP1u RBD binding to hTfR ECD . (A) Experimental scheme. hTfR ECD was immobilized on Ni-NTA BLI biosensors, then introduced into the kinetic buffer with or without FTH1, and subsequently into buffer containing GST-VP1u RBD <t>.</t> <t>Maltose-binding</t> protein (MBP) served as a control for non-specific binding. (B) Dose-dependent inhibition of VP1u binding to hTfR by FTH1. Sensograms show progressively reduced association and dissociation of hTfR ECD with GST-VP1u RBD after the introduction of FTH1 at the indicated concentrations. MBP served as a control at 4 µM. (C) Quantification of FTH1 inhibition of B19V internalization. CD36 + EPCs were incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C, followed by B19V infection (MOI=3,000) at 37°C for 1 h. After treatment with trypsin, the cells were washed with PBS, and viral DNA was extracted for quantification of internalized B19V by relative viral DNA levels normalized to mitochondrial DNA. (D) FTH1 inhibits B19V infection. CD36 + EPCs were pre-incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C followed by B19V infection (MOI=1,000) at 37°C for 1 day. At 1 dpi, the cells were collected for quantification of B19V DNA levels. Data are presented relative to the corresponding control-treated cell group at each concentration. Experiments were performed in triplicate, and data shown are mean ± SD, and were analyzed by one-way ANOVA with Dunnett’s test (****P < 0.0001) (E&F) Cell cycle analysis. An EdU incorporation assay was performed in CD36 + EPCs with the indicated treatments, followed by flow cytometry analysis. (E) Flow cytometry histograms. Representative histograms show the cell cycles of mock, 10 µM FTH1-, and 10 µM MBP-treated CD36 + EPCs. (F) Quantification of the percentage of the indicated cell populations in G2/M, S, or G1 phase. Data shown are the mean ± SD from three independent experiments. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; ns, not significant).
Recombinant Maltose Binding Protein (Mbp, supplied by Obetech LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+maltose/recombinant+maltose+binding+protein++mbp/pm25045929-64-33-43
Average 90 stars, based on 1 article reviews
recombinant maltose binding protein (mbp - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
recombinant maltose binding protein-major outer membrane protein (mbp-momp) from c. muridarum  (rocky mountain labs)
90
rocky mountain labs recombinant maltose binding protein-major outer membrane protein (mbp-momp) from c. muridarum
Ferritin heavy chain 1 (FTH1) competes with B19V VP1u for binding to hTfR, thereby inhibiting B19V internalization and replication in CD36 + EPCs. (A&B) BLI analysis of FTH1 inhibition of GST-VP1u RBD binding to hTfR ECD . (A) Experimental scheme. hTfR ECD was immobilized on Ni-NTA BLI biosensors, then introduced into the kinetic buffer with or without FTH1, and subsequently into buffer containing GST-VP1u RBD <t>.</t> <t>Maltose-binding</t> protein (MBP) served as a control for non-specific binding. (B) Dose-dependent inhibition of VP1u binding to hTfR by FTH1. Sensograms show progressively reduced association and dissociation of hTfR ECD with GST-VP1u RBD after the introduction of FTH1 at the indicated concentrations. MBP served as a control at 4 µM. (C) Quantification of FTH1 inhibition of B19V internalization. CD36 + EPCs were incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C, followed by B19V infection (MOI=3,000) at 37°C for 1 h. After treatment with trypsin, the cells were washed with PBS, and viral DNA was extracted for quantification of internalized B19V by relative viral DNA levels normalized to mitochondrial DNA. (D) FTH1 inhibits B19V infection. CD36 + EPCs were pre-incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C followed by B19V infection (MOI=1,000) at 37°C for 1 day. At 1 dpi, the cells were collected for quantification of B19V DNA levels. Data are presented relative to the corresponding control-treated cell group at each concentration. Experiments were performed in triplicate, and data shown are mean ± SD, and were analyzed by one-way ANOVA with Dunnett’s test (****P < 0.0001) (E&F) Cell cycle analysis. An EdU incorporation assay was performed in CD36 + EPCs with the indicated treatments, followed by flow cytometry analysis. (E) Flow cytometry histograms. Representative histograms show the cell cycles of mock, 10 µM FTH1-, and 10 µM MBP-treated CD36 + EPCs. (F) Quantification of the percentage of the indicated cell populations in G2/M, S, or G1 phase. Data shown are the mean ± SD from three independent experiments. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; ns, not significant).
Recombinant Maltose Binding Protein Major Outer Membrane Protein (Mbp Momp) From C. Muridarum, supplied by rocky mountain labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+maltose/recombinant+maltose+binding+protein+major+outer+membrane+protein++mbp+momp++from+c++muridarum/pm20064144-50-10-23
Average 90 stars, based on 1 article reviews
recombinant maltose binding protein-major outer membrane protein (mbp-momp) from c. muridarum - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
maltose binding protein-cdc25c recombinant enzyme  (GTP Technology)
90
GTP Technology maltose binding protein-cdc25c recombinant enzyme
Ferritin heavy chain 1 (FTH1) competes with B19V VP1u for binding to hTfR, thereby inhibiting B19V internalization and replication in CD36 + EPCs. (A&B) BLI analysis of FTH1 inhibition of GST-VP1u RBD binding to hTfR ECD . (A) Experimental scheme. hTfR ECD was immobilized on Ni-NTA BLI biosensors, then introduced into the kinetic buffer with or without FTH1, and subsequently into buffer containing GST-VP1u RBD <t>.</t> <t>Maltose-binding</t> protein (MBP) served as a control for non-specific binding. (B) Dose-dependent inhibition of VP1u binding to hTfR by FTH1. Sensograms show progressively reduced association and dissociation of hTfR ECD with GST-VP1u RBD after the introduction of FTH1 at the indicated concentrations. MBP served as a control at 4 µM. (C) Quantification of FTH1 inhibition of B19V internalization. CD36 + EPCs were incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C, followed by B19V infection (MOI=3,000) at 37°C for 1 h. After treatment with trypsin, the cells were washed with PBS, and viral DNA was extracted for quantification of internalized B19V by relative viral DNA levels normalized to mitochondrial DNA. (D) FTH1 inhibits B19V infection. CD36 + EPCs were pre-incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C followed by B19V infection (MOI=1,000) at 37°C for 1 day. At 1 dpi, the cells were collected for quantification of B19V DNA levels. Data are presented relative to the corresponding control-treated cell group at each concentration. Experiments were performed in triplicate, and data shown are mean ± SD, and were analyzed by one-way ANOVA with Dunnett’s test (****P < 0.0001) (E&F) Cell cycle analysis. An EdU incorporation assay was performed in CD36 + EPCs with the indicated treatments, followed by flow cytometry analysis. (E) Flow cytometry histograms. Representative histograms show the cell cycles of mock, 10 µM FTH1-, and 10 µM MBP-treated CD36 + EPCs. (F) Quantification of the percentage of the indicated cell populations in G2/M, S, or G1 phase. Data shown are the mean ± SD from three independent experiments. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; ns, not significant).
Maltose Binding Protein Cdc25c Recombinant Enzyme, supplied by GTP Technology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+maltose/maltose+binding+protein+cdc25c+recombinant+enzyme/pm16170030-63-8-16
Average 90 stars, based on 1 article reviews
maltose binding protein-cdc25c recombinant enzyme - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
recombinant e coli maltose binding protein protein  (Novus Biologicals)
N/A
The Recombinant E coli Maltose Binding Protein Protein from Novus Biologicals is derived from E coli The Recombinant E coli Maltose Binding Protein Protein has been validated for the following applications SDS Page
   Buy from Supplier

Image Search Results


Ferritin heavy chain 1 (FTH1) competes with B19V VP1u for binding to hTfR, thereby inhibiting B19V internalization and replication in CD36 + EPCs. (A&B) BLI analysis of FTH1 inhibition of GST-VP1u RBD binding to hTfR ECD . (A) Experimental scheme. hTfR ECD was immobilized on Ni-NTA BLI biosensors, then introduced into the kinetic buffer with or without FTH1, and subsequently into buffer containing GST-VP1u RBD . Maltose-binding protein (MBP) served as a control for non-specific binding. (B) Dose-dependent inhibition of VP1u binding to hTfR by FTH1. Sensograms show progressively reduced association and dissociation of hTfR ECD with GST-VP1u RBD after the introduction of FTH1 at the indicated concentrations. MBP served as a control at 4 µM. (C) Quantification of FTH1 inhibition of B19V internalization. CD36 + EPCs were incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C, followed by B19V infection (MOI=3,000) at 37°C for 1 h. After treatment with trypsin, the cells were washed with PBS, and viral DNA was extracted for quantification of internalized B19V by relative viral DNA levels normalized to mitochondrial DNA. (D) FTH1 inhibits B19V infection. CD36 + EPCs were pre-incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C followed by B19V infection (MOI=1,000) at 37°C for 1 day. At 1 dpi, the cells were collected for quantification of B19V DNA levels. Data are presented relative to the corresponding control-treated cell group at each concentration. Experiments were performed in triplicate, and data shown are mean ± SD, and were analyzed by one-way ANOVA with Dunnett’s test (****P < 0.0001) (E&F) Cell cycle analysis. An EdU incorporation assay was performed in CD36 + EPCs with the indicated treatments, followed by flow cytometry analysis. (E) Flow cytometry histograms. Representative histograms show the cell cycles of mock, 10 µM FTH1-, and 10 µM MBP-treated CD36 + EPCs. (F) Quantification of the percentage of the indicated cell populations in G2/M, S, or G1 phase. Data shown are the mean ± SD from three independent experiments. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; ns, not significant).

Journal: bioRxiv

Article Title: Identification of Human Transferrin Receptor as an Entry Co-receptor for Parvovirus B19 Infection of Human Erythroid Progenitor Cells

doi: 10.64898/2026.04.02.715920

Figure Lengend Snippet: Ferritin heavy chain 1 (FTH1) competes with B19V VP1u for binding to hTfR, thereby inhibiting B19V internalization and replication in CD36 + EPCs. (A&B) BLI analysis of FTH1 inhibition of GST-VP1u RBD binding to hTfR ECD . (A) Experimental scheme. hTfR ECD was immobilized on Ni-NTA BLI biosensors, then introduced into the kinetic buffer with or without FTH1, and subsequently into buffer containing GST-VP1u RBD . Maltose-binding protein (MBP) served as a control for non-specific binding. (B) Dose-dependent inhibition of VP1u binding to hTfR by FTH1. Sensograms show progressively reduced association and dissociation of hTfR ECD with GST-VP1u RBD after the introduction of FTH1 at the indicated concentrations. MBP served as a control at 4 µM. (C) Quantification of FTH1 inhibition of B19V internalization. CD36 + EPCs were incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C, followed by B19V infection (MOI=3,000) at 37°C for 1 h. After treatment with trypsin, the cells were washed with PBS, and viral DNA was extracted for quantification of internalized B19V by relative viral DNA levels normalized to mitochondrial DNA. (D) FTH1 inhibits B19V infection. CD36 + EPCs were pre-incubated with FTH1 or MBP control (at the indicated concentrations) at 4°C followed by B19V infection (MOI=1,000) at 37°C for 1 day. At 1 dpi, the cells were collected for quantification of B19V DNA levels. Data are presented relative to the corresponding control-treated cell group at each concentration. Experiments were performed in triplicate, and data shown are mean ± SD, and were analyzed by one-way ANOVA with Dunnett’s test (****P < 0.0001) (E&F) Cell cycle analysis. An EdU incorporation assay was performed in CD36 + EPCs with the indicated treatments, followed by flow cytometry analysis. (E) Flow cytometry histograms. Representative histograms show the cell cycles of mock, 10 µM FTH1-, and 10 µM MBP-treated CD36 + EPCs. (F) Quantification of the percentage of the indicated cell populations in G2/M, S, or G1 phase. Data shown are the mean ± SD from three independent experiments. Statistical significance was determined by two-way ANOVA with Dunnett’s multiple comparisons test (****P < 0.0001; ns, not significant).

Article Snippet: Recombinant Maltose-binding protein (MBP) (#NBC1-18538) was purchased from Novus Biologicals (Centennial, CO).

Techniques: Binding Assay, Inhibition, Control, Incubation, Infection, Concentration Assay, Cell Cycle Assay, Flow Cytometry